Abstract
Forty-four (44) patients with Burkitt's lymphoma received identical combination chemotherapy on the basis of body surface area. Patients with renal dysfunction, more common in those with abdominal tumours, were at significantly greater risk of developing severe leucopenia (less than 1000 cells/dl) than those with normal renal function (P less than 0.0001). Similar results were seen in a series of 8 patients with normal marrows treated with only i.v. cyclophosphamide and intrathecal methotrexate. Giving a lower initial dose of cyclophosphamide seemed to reduce the risk of severe leucopenia in 5 additional patients with evidence of renal dysfunction. The mechanism is postulated as delayed excretion of the active metabolites of cyclophosphamide. Adjustment of the chemotherapeutic dose should be considered when treating patients with renal dysfunction.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagley C. M., Jr, Bostick F. W., DeVita V. T., Jr Clinical pharmacology of cyclophosphamide. Cancer Res. 1973 Feb;33(2):226–233. [PubMed] [Google Scholar]
- Chabner B. A., Myers C. E., Coleman C. N., Johns D. G. The clinical pharmacology of antineoplastic agents (second of two parts). N Engl J Med. 1975 May 29;292(22):1159–1168. doi: 10.1056/NEJM197505292922206. [DOI] [PubMed] [Google Scholar]
- Krakoff I. H., Murphy M. L. Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics. 1968 Jan;41(1):52–56. [PubMed] [Google Scholar]
- WRIGHT D. H. BURKITT'S TUMOUR. A POST-MORTEM STUDY OF 50 CASES. Br J Surg. 1964 Apr;51:245–251. doi: 10.1002/bjs.1800510404. [DOI] [PubMed] [Google Scholar]